Failure Narrows Odds On Targacept Depression Drug; Hope Rests In Remaining Three Trials

Nicotinic receptor company Targacept and TC-5214 partner AstraZeneca remain committed to a 2H 2012 filing of the drug as adjunct therapy for major depressive disorder.